by Portfolio Grader | January 16, 2013 4:00 pm
This week, four Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
This week, Aegerion Pharmaceuticals (NASDAQ:AEGR) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. Shares of AEGR have increased 21.5% over the past month, better than the 4.7% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of AEGR stock.
Gentium (NASDAQ:GENT) shows solid improvement this week. The company’s rating rises from a B to an A. Gentium is a biopharmaceutical company focused on the discovery, research, development, and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. For more information, get Portfolio Grader’s complete analysis of GENT stock.
Novavax’s (NASDAQ:NVAX) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Novavax creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. Wall Street seems to agree with the upgrade and has propelled the stock up 14.4% over the past month. For more information, get Portfolio Grader’s complete analysis of NVAX stock.
This week, China Biologic Products’ (NASDAQ:CBPO) ratings are up from a B last week to an A. China Biologic Products is a biopharmaceutical company that engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 25.5% over the past month. For more information, get Portfolio Grader’s complete analysis of CBPO stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/01/4-biotechnology-stocks-to-buy-now-aegr-gent-nvax/
Short URL: http://investorplace.com/?p=291936
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.